# Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP

> **NCT03196947** · PHASE1,PHASE2 · TERMINATED · sponsor: **Allarity Therapeutics** · enrollment: 1 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** APO010

## Key facts

- **NCT ID:** NCT03196947
- **Lead sponsor:** Allarity Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-13
- **Primary completion:** 2020-01-16
- **Final completion:** 2020-01-16
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The study was terminated early due to sponsors decision
- **Last updated:** 2020-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03196947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03196947, "Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03196947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*